CVAC Stock Summary and Trading Ideas (Curevac N.V. - | NASDAQ:CVAC)

CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

Curevac N.V. - trades on the NASDAQ stock market under the symbol CVAC.

As of January 9, 2026, CVAC stock price was flat at $4.66 with million shares trading.

CVAC has a beta of 0.96, meaning it tends to be less sensitive to market movements. CVAC has a correlation of 0.09 to the broad based SPY ETF.

CVAC has a market cap of $1.05 billion. This is considered a Small Cap stock.

Last quarter Curevac N.V. - reported $63 million in Revenue and $1.41 earnings per share. This beat revenue expectation by $49 million and exceeded earnings estimates by $1.58.

In the last 3 years, CVAC traded as high as $12.79 and as low as $2.22.

CVAC has underperformed the market in the last year with a return of +10.2%, while the SPY ETF gained +19.0%. In the last 3 month period, CVAC fell short of the market, returning -13.9%, while SPY returned +3.7%. However, in the most recent 2 weeks CVAC has outperformed the stock market by returning +8.4%, while SPY returned +0.5%.

CVAC support price is $4.53 and resistance is $4.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CVAC shares will trade within this expected range on the day.